Does RGS6 upregulation or D2 autoreceptor modulation prevent neurodegeneration in established Parkinson's models?¶

Notebook ID: nb-SDA-2026-04-17-gap-pubmed-20260410-145520-5692b02e · Analysis: SDA-2026-04-17-gap-pubmed-20260410-145520-5692b02e
Domain: neurodegeneration · Date: 2026-04-17

Research Question¶

While RGS6 deficiency causes Parkinson's-like pathology, whether enhancing RGS6 function or targeting the D2R-Gi/o pathway can reverse or prevent established neurodegeneration remains untested. This is crucial for therapeutic development.

Gap type: open_question Source paper: Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice. (2019, JCI Insight, PMID:31120439)

Debate Summary¶

Debate transcript not available for this analysis.

Hypotheses Ranked by Composite Score¶

Total hypotheses: 7

Title	Composite	Confidence	Novelty	Feasibility	Impact
AMPK Activation to Restore Autophagy and Clear α-Synuclein Aggregates	0.559	0.4	0.5	0.7	0.6
NRF2 Activation to Counteract Oxidative Stress from RGS6 Deficiency	0.518	0.45	0.45	0.6	0.55
GSK3β Inhibition to Prevent α-Synuclein Phosphorylation and Aggregation	0.429	0.35	0.35	0.5	0.45
AAV-Mediated RGS6 Overexpression in Substantia Nigra Parvocellular Neurons	0.424	0.25	0.7	0.3	0.55
D2 Autoreceptor Partial Agonism as Compensatory Therapy for RGS6 Deficiency	0.348	0.2	0.35	0.55	0.3
Combination Gene Therapy Targeting RGS6 and Parkin or PINK1 to Address Mitochond	0.317	0.15	0.6	0.15	0.4
PDE10A Inhibition to Bypass RGS6 Deficiency via cAMP Pathway Normalization	0.224	0.15	0.3	0.25	0.2

Knowledge Graph Edges¶

Total edges: 3

Source	Relation	Target	Evidence
GSK3β	associated_with	neurodegeneration	0.429
AAV-Mediated RGS6	associated_with	neurodegeneration	0.424
D2 Autoreceptor Partial	associated_with	neurodegeneration	0.348

Key Citations¶

No citations found for this analysis.

---

View analysis on SciDEX · Browse all analyses · Browse notebooks